Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains


**Synthesis of Epigenetic Regulator I-BET762 (GSK525762)**

---

**Significance:** I-BET762 (GSK525762) has entered phase I/II clinical trials for the treatment of the aggressive NUT midline carcinoma and other cancers. It disrupts the function of the bromo-domain and extra-terminal domain (BET) family of proteins. The synthesis depicted features the construction of the 1,4-benzodiazepine skeleton with incorporation of an (S)-aspartic acid moiety.

**Comment:** For a synthesis of benzophenone A, see: C.-w. Chung et al. *J. Med. Chem.* 2011, 54, 3827. The easy epimerization of the stereogenic center that occurs in the thionation reaction (B → C) was suppressed by conducting the reaction in the presence of sodium carbonate. The (R)-enantiomer is biologically inactive as a BET inhibitor.

---

**SYNFACTS Contributors:** Philip Kocienski

*SYNFACTS* Contributors: Philip Kocienski

Synfacts 2014, 10(1), 0010 Published online: 13.12.2013

**DOI:** 10.1055/s-0033-1340327; **Reg-No.:** K07313SF